Status:

COMPLETED

Protein-Prebiotic Wellbeing Study

Lead Sponsor:

Arizona State University

Collaborating Sponsors:

FrieslandCampina

Conditions:

Digestive Health

Quality of Life

Eligibility:

All Genders

18-35 years

Phase:

NA

Brief Summary

Healthy participants with self-reported GI complaints will consume the protein supplement that they normally use for recovery purposes after exercise during a 3-week baseline period, followed by a 3-w...

Detailed Description

A substantial number of athletes suffer from gastro-intestinal problems, which may impair performance and/or subsequent recovery. Also, gut barrier integrity is impaired with high-intensity training. ...

Eligibility Criteria

Inclusion

  • Healthy subjects living in Arizona in the USA
  • Women/Men aged between 18-35 years
  • Serious athletes (exercise at least 3 x per week)
  • With or without GI tract issues due to sport or protein/diet intake
  • 5 ≤ BMI ≤ 40 kg/m2
  • No physical limitations (i.e. able to perform all activities associated with daily living in an independent manner).
  • Use of a protein supplement or sports food after at least one training per day 3 x per week
  • Willing to slightly increase their protein supplement intake during the intervention phase for 21 consecutive days
  • Stable weight during the last 4 weeks, without a focus on body weight reduction through limiting caloric intake
  • Written informed consent

Exclusion

  • Daily use of (sport) supplements containing probiotics and/or prebiotics
  • Smoking
  • Self-reported cow's milk protein allergy
  • Clinical lactose intolerance
  • Clinical milk protein allergy
  • House dust mite allergy
  • Diagnosed GI tract disorders or diseases
  • Musculoskeletal disorders
  • Metabolic disorders (such as diabetes)
  • Use of any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescribed acne medications).
  • Chronic use of gastric acid-suppressing medication or anti-coagulants
  • Use of antibiotics or anti-inflammatory medication the past 2 weeks
  • Blood donation in the past 2 months
  • Pregnant/lactating women
  • Athletes should not aim to lose body weight by reducing energy intake during the study

Key Trial Info

Start Date :

January 26 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 11 2022

Estimated Enrollment :

98 Patients enrolled

Trial Details

Trial ID

NCT05303753

Start Date

January 26 2022

End Date

July 11 2022

Last Update

April 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Arizona State University

Phoenix, Arizona, United States, 85004